Organon

Industry

  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • Alydia Health
  • Dermavant Sciences
  • Forendo Pharma
  • Forendo Pharma Oy
  • Organon & Co.
  • Organon NV
See more in Biomedtracker

Latest on Organon

Pink Sheet

Semaglutide For MASH Among Raft Of New EU Filings

 
• By Neena Brizmohun

The European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc

Scrip

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down

 
• By Mandy Jackson

Dozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation

Scrip

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

Generics Bulletin

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

 
• By Dean Rudge

Organon believes there is “considerable growth potential” for the Tofidence (tocilizumab-bavi) biosimilar to Genentech’s Actemra, after acquiring rights in the US for the product from Biogen, in a dea